Bijker Martijn S, Melief Cornelis J M, Offringa Rienk, van der Burg Sjoerd H
Leiden University Medical Center, Department of Immunohematology, Leiden, The Netherlands.
Expert Rev Vaccines. 2007 Aug;6(4):591-603. doi: 10.1586/14760584.6.4.591.
Synthetic peptide vaccines aiming at the induction of a protective CD8(+) T-cell response against infectious or malignant diseases are widely used in the clinic but, despite their success in animal models, they do not yet live up to their promise in humans. This review assesses the development of synthetic peptide vaccines, weighs it against the immunological concepts that have emerged, and identifies the key issues that play a role in the failure or success of a synthetic peptide vaccine. The current state-of-the-art peptide vaccine is a complete synthetic inflammatory product that is ingested by professional antigen-presenting cells and stimulates both CD4(+) and CD8(+) T cells.
旨在诱导针对感染性疾病或恶性疾病的保护性CD8(+) T细胞反应的合成肽疫苗在临床上广泛应用，然而，尽管它们在动物模型中取得了成功，但在人类中尚未达到预期效果。本综述评估了合成肽疫苗的发展，将其与已出现的免疫学概念进行权衡，并确定了在合成肽疫苗成败中起作用的关键问题。当前最先进的肽疫苗是一种完全合成的炎症产物，可被专职抗原呈递细胞摄取，并刺激CD4(+)和CD8(+) T细胞。
